Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Mesoblast Limited announced that it has filed for orphan drug designation and rare pediatric disease designation with the United States Food and Drug Administration for its allogeneic cell therapy Revascor® in the treatment of the congenital heart disease hypoplastic left heart syndrome.